Uncategorized
Shire submits new drug application for lifitegrast
Shire submitted a new drug application with the FDA for the approval of its investigational compound lifitegrast for the treatment of dry eye disease in adults, according to a press release.The submission is based on results from four clinical trials, which included one phase 2 study, two phase 3 efficacy and safety studies, and one long-term phase 3 safety study, the release said. More than 1,800 subjects were involved in the studies.